Emavusertib mesylate

Overview

Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib ( HY-135317 ). Emavusertib mesylate is an orally active inhibitor for IRAK4 ( IC 50 =57 nM) and FLT3 . Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10 , thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis . Emavusertib mesylate exhibits antitumor activity in mouse model.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > IRAK | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > MyD88

Product Information

• Catalog No.: HY-135317D
• CAS No.: 2376399-40-3
• Molecular Formula: C25H29N7O8S
• Molecular Weight: 587.60
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source